

The Interplay Between the Tumour Microenvironment and Myeloid Cells in Bladder Cancer Immunotherapy Resistance



NIHR | Manchester Biomedical Research Centre

Fraser Child¹, Conrado Guerrero Quiles¹, Sapna Luni¹, Julie Gough², Martin Humphries³, Ananya Choudhury^{1,4}

¹Division of Cancer Sciences, University of Manchester, UK

²Department of Materials & Henry Royce Institute, University of Manchester, UK

³Manchester Cell-Matrix Centre, Division of Cell Matrix Biology & Regenerative Medicine, School of Biology, Medicine & Health, University of Manchester, UK

⁴The Christie NHS Foundation Trust, Manchester, UK

PRINTED BY
SCIENCEPOSTERS
.com


MANCHESTER
1824

The University of Manchester

INTRODUCTION

- Bladder cancer (BlCa) is the only top-10 cancer without improved prognosis rates in the last 20 years [1].
- Combining immune checkpoint inhibitors (ICI) with extracellular matrix (ECM)-targeting antibody-drug conjugates has doubled overall survival in muscle-invasive bladder cancer (MIBC) patients compared to chemotherapy alone [2].
- While PD-1/PD-L1 blockade has improved bladder cancer survival rates, only 20% of patients have a sustained response [3].
- Hypoxia is a hallmark of solid tumours and a feature of ~70% of solid BlCa tumours [4].
- Neutrophil infiltration is a poor prognostic marker associated with hypoxia in MIBC [5, 6] but, the immunosuppressive pro-tumour mechanisms are unclear.


NEUTROPHILS PROMOTE BLADDER CANCER IN RESPONSE TO HYPOXIA



EXPERIMENTAL AIMS:

- Determine whether hypoxia-associated extracellular proteins can induce polarisation of pro-tumour neutrophils.
- Identify biomarker(s) for patient stratification to determine who will benefit from immunotherapy.
- Test novel therapeutic strategies that synergise with immunotherapies.

METHODOLOGY



REFERENCES

1. Sung, H. et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*, 2021. 71(3): p. 209-249.

2. Powles, T. et al., EV-302 Trial Investigators. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. *N Engl J Med*, 2024. Mar 7;390(10):875-888.

3. Li, F. et al., The efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials. *Aging (Albany NY)*, 2021. 13(10): p. 20468-20480.

4. Hoskin, P.J. et al., The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma. *Radiotherapy and oncology*, 2004. 72(2): p. 159-168.

5. Shen, M. et al., Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. *PLoS one*, 2014. 9(6): p. e98259.


6. Jing, W. et al., Tumor-neutrophil cross talk orchestrates the tumor microenvironment to determine the bladder cancer progression. *Proceedings of the National Academy of Sciences*, 2024. 121(20): p. e231285121.

7. Korbecki, J. et al., The Role of CXCR1, CXCR2, CXCR3, CXCR4, and CXCR6 Ligands in Molecular Cancer Processes and Clinical Aspects of Acute Myeloid Leukemia (AML). *Cancers*, 2023. 15(18): p. 4555.

8. Murali Vignarajah et al., Regulation of ICAM-1 in human neutrophils, *Journal of Leukocyte Biology*, Volume 116, Issue 4, October 2024, 916) : p. e98259.


RESULTS

HYPOXIC BLADDER CANCER APPEARS TO ALTER ECM AND NEUTROPHIL FUNCTIONS




- a) Proteomic profiling of hypoxic (0.2% O₂) T24-CM showed the presence of chemokines: CXCL1, CXCL6 and CXCL8, which are known ligands of the commonly expressed tumour-associated neutrophil receptor CXCR2 [7].
- Pathway enrichment analysis shows these chemokines are associated with neutrophil activation, degranulation, and general neutrophil-mediated immunity. Whereas, IL-6 was associated with factors involved in ECM remodelling processes.


“ANTI-TUMOUR IMMUNE STIMULATORY” NEUTROPHIL SUBTYPE IS ENRICHED IN NORMOXIC (21%O₂) T24-CONDITIONED MEDIA VERSUS HYPOXIC (1% AND 0.2% O₂)



- tSNE and clustering analysis identified four phenotypically distinct neutrophil subtypes following incubation in 21%, 1% and 0.2% O₂ T24-CM (Left).
- ICAM1⁺ “anti-tumour T cell-stimulating” population was significantly enriched in the normoxic CM while the hypoxic CM stimulated more “unprimed/inactive” CD62L⁺ neutrophils with potential immune suppressive tumour-promoting capacity (Right) (n=3).



TNF-ALPHA DOES NOT STIMULATE THE NEUTROPHILS SEEN IN T24-CM



- tSNE and clustering analysis identified five phenotypically distinct neutrophil clusters following incubation in unstimulated RPMI media, RPMI +20ng/mL TNF-alpha and RPMI +20ng/mL TGF-beta.
- Combination and concentration of cytokines are likely crucial to drive the expression of CD62L and ICAM1 in the four neutrophil subtypes following culture in T24-CM.

SUMMARY, WORKING HYPOTHESIS & FUTURE DIRECTIONS

